{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:39:06Z","timestamp":1784259546117,"version":"3.55.0"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Trifluridine-tipiracil (FTD\/TPI) is approved as monotherapy and in combination with bevacizumab for the treatment of metastatic colorectal cancer (mCRC). This UK real-world retrospective analysis aimed to evaluate the use of granulocyte colony stimulating factor (G-CSF) to prevent FTD\/TPI induced neutropenia in patients with mCRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective data were collected across five UK Healthcare sites. Consecutive patients with mCRC having received at least 2 cycles of FTD\/TPI in addition to G-CSF administered as primary or secondary prophylaxis were included. The study assessed the timing and duration of G-CSF treatment, incidence of neutropenia, and subsequent dose delays\/reductions. Time on FTD\/TPI treatment, Progression free Survival (PFS), and Overall Survival (OS) were also calculated for this patient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The data set included 55 mCRC patients in total; 25 receiving primary prophylaxis, and 30 receiving secondary prophylaxis. 68% of G-CSF prophylaxis commenced on day 15, with 99% initiated between days 14 and 22. Following G-CSF use, 25% of patients experienced a dose delay and 18% a dose reduction due to neutropenia. 14.5% of patients reported grade \u22653 neutropenia. In patients receiving primary prophylaxis a mean of 18.4\u00a0weeks of FTD\/TPI were completed, whereas in those receiving secondary prophylaxis the mean was 28.8\u00a0weeks. Primary prophylaxis patients exhibited a median PFS of 3\u00a0months, and a median OS of 9.7\u00a0months. In secondary prophylaxis patients the median PFS was 7.2\u00a0months and the median OS 17.5\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>G-CSF prophylaxis reduced the incidence of neutropenia, improved dose intensity, and extended PFS and OS in this real-world study of mCRC patients on FTD\/TPI. G-CSF prophylaxis was commonly administered as a 5-day course of filgrastim starting on day 15.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748251374798","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:22:50Z","timestamp":1759749770000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Granulocyte Colony Stimulating Factor in the Prevention of Chemotherapy-Induced Neutropenia in Patients With Colorectal Cancer Receiving Trifluridine\/Tipiracil: A Real-World UK Retrospective Review"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7793-0009","authenticated-orcid":false,"given":"Ian","family":"Purcell","sequence":"first","affiliation":[{"name":"Pharmacy Department, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Potter","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospitals Coventry &amp; Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bell","sequence":"additional","affiliation":[{"name":"Servier Laboratories Limited, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Brooks","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharath","family":"Gangadhara","sequence":"additional","affiliation":[{"name":"Department of Oncology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Kunene","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Jing","family":"Teo","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maira","family":"Iqbal Malik","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospitals Coventry &amp; Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"e_1_3_8_2_2","unstructured":"European Medicines Agency. Lonsurf European Public Assessment Report (EPAR). Lonsurf. European Medicines Agency (EMA); 2023. Accessed July 22 2025."},{"key":"e_1_3_8_3_2","unstructured":"Medicines and Healthcare products regulatory agency MHRA products | home 2023. Accessed 22 July 2025."},{"key":"e_1_3_8_4_2","unstructured":"Lonsurf 15 mg\/6.14 mg film-coated tablets summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/7309\/smpc. 2024. Accessed July 22 2025."},{"key":"e_1_3_8_5_2","first-page":"567","article-title":"Neutropenia and quality of life: economic, psychological perspectives for patients and caregivers","volume":"14","author":"Xuin F","year":"2023","unstructured":"Xuin F. Neutropenia and quality of life: economic, psychological perspectives for patients and caregivers. J Blood Disord Transfus. 2023;14:567.","journal-title":"J Blood Disord Transfus"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214963"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq195"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.10.013"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000752"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.009"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.005"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.601"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2022.2536"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103193"},{"key":"e_1_3_8_19_2","unstructured":"European Medicines Agency. Filgrastim European public assessment report (EPAR). 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/filgrastim-hexal. Accessed July 22 2025."},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0643"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf099"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251374798","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748251374798","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251374798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:24:00Z","timestamp":1777386240000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748251374798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":20,"alternative-id":["10.1177\/10732748251374798"],"URL":"https:\/\/doi.org\/10.1177\/10732748251374798","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/10732748251374798\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251374798\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251374798\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251374798\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251374798\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251374798\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251374798\/v2\/review1","asserted-by":"object"}]},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"10732748251374798"}}